Kareus Therapeutics SA has entered a broad strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials. Quintiles will make an undisclosed investment in Kareus through an equity investment and access to clinical service on a shared-risk basis. Kareus plans to submit an IND application for KU-046, a new chemical entity for the treatment of Alzheimer’s disease. Kareus has also identified a lead series of molecules for the treatment of Type-2 diabetes and will select a clinical candidate for development later in 2011. Quintiles will conduct Phase I trials for both KU-046 and the diabetes candidate.

Tom Perkins, senior vice president of corporate development for Quintiles, said, “This agreement is an example of how leading biotechnology companies are building partnerships that extend beyond the traditional licensing model to manage risk, increase productivity, and increase value to stakeholders. We are pleased that Kareus has chosen to leverage Quintiles’ suite of comprehensive services, including our new Phase I research unit in Hyderabad, India.”